Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to discovering, developing, and delivering life-changing therapeutics for patients in need, today ...

William Blair restated their outperform rating on shares of Xenon Pharmaceuticals (NASDAQ:XENE – Free Report) in a report ...

Xenon Pharmaceuticals XENE reported a loss of 84 cents per share for the fourth quarter of 2024, narrower than the Zacks Consensus Estimate of a loss of 89 cents. The company had incurred a loss of 64 ...

Xenon Pharmaceuticals Inc. (NASDAQ:XENE – Get Free Report) has earned an average rating of “Buy” from the nine ratings firms that are covering the company, MarketBeat Ratings reports.

Recompiled project, XenonRecomp does something similar, except for the PowerPC-equipped Microsoft Xbox 360 game console. Based around the triple-core IBM CPU codenamed ...

“We expect the next 12 to 24 months will represent a catalyst-rich period for Xenon as we continue to advance our deep pipeline of promising late- and early-stage programs across multiple neurological ...

Xenon's discovery concluded an intense period of research on noble gases. Much heavier than neon and krypton, it had not been explicitly predicted, and was sufficiently rare to avoid chance detection.

BURNABY, British Columbia — BURNABY, British Columbia — Xenon Pharmaceuticals Inc. (XENE) on Thursday reported a loss of $65.7 million in its fourth quarter. On a per-share basis, the Burnaby, British ...

Detailed price information for Xenon Pharmaceuticals Inc (XENE-Q) from The Globe and Mail including charting and trades.

The original Xenon processor’s architecture implements 3 PPC via the PowerPC instruction set created by IBM. Therefore, the ...

A live audio webcast of the company presentation will be available on the "Investors” section of Xenon's website and posted for replay following the event. The above listed dates and times are subject ...